Glaucoma and Quality of Life

Biggerstaff, Kristin; Lin, Albert P.

doi:10.1097/iio.0000000000000230

Cited by 19 publications

(13 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are compelling, support the MIGS procedure with this device, and show an improved CDVA. This particular MIGS surgery provides an opportunity to decrease complications after surgery through the physiological pathway of the device, reduces costs, since it lessens the financial burden of glaucoma for patients and government, [1] and improves quality of vision and QoL [14].…”

Section: Discussionmentioning

confidence: 99%

Micro-Invasive Glaucoma Surgery with the iStent inject: Impact on IOP and Medication Burden in a Real-World Setting

Alharbi¹

2020

OJOph

View full text Add to dashboard Cite

Background: The iStent inject is a Micro-Invasive Glaucoma Surgical (MIGS) device that has shown to reduce IOP and to be safe for glaucoma patients with fewer complications than regular surgery. Objective: To investigate, up to 15-20 months, the efficacy and safety of implantation of two second-generation trabecular microbypass stents in patients with or without prior glaucoma surgery. Methods: Fifty-seven eyes were implanted with the iStent inject. The population was comprised of eyes with primary open-angle glaucoma (n = 51), pseudoexfoliation glaucoma (n = 5) and ocular hypertension (n = 1). Major outcome parameters included IOP, medication needs and corrected distance visual acuity (CDVA). Follow-up time points were one day, 2-4 months, 9-14 months and 15-20 months. Results: The main reason to perform MIGS was IOP reduction in 68.4%, reduced number of medications due to drug intolerance in 24.6% and reduced medication due to compliance issues in 7.0% of the eyes. IOP decreased by 22.47%, from 19.40 ± 3.83 mmHg preoperatively (preop) to 15.04 ± 1.67 mmHg at 15-20 months postoperatively. IOP reduction was achieved at all follow-up time points (p < 0.001). A decrease in the number of medications was achieved in 32.1% of the patients after 15-20 months. Conclusions: Insertion of the iStent inject in patients with or without prior glaucoma surgery shows effective and sustained improvements in IOP with no safety concerns.

show abstract

Section: Discussionmentioning

confidence: 99%

Micro-Invasive Glaucoma Surgery with the iStent inject: Impact on IOP and Medication Burden in a Real-World Setting

Alharbi¹

2020

OJOph

View full text Add to dashboard Cite

show abstract

“…Феноменологическое исследование населения Италии выявило, что пациенты с глаукомой испытывают постоянные физиологические и психологические проблемы [26,27]. Изучение влияния изменений периферического поля зрения на качество жизни пациентов показало, что дефицит поля зрения более неблагоприятен, чем даже ухудшение остроты зрения, особенно при локализации дефекта поля зрения в нижней полусфере [28,29]. При этом особенно снижается качество жизни при необходимости зрительной работы на близком расстоянии, ходьбе, работе в условиях низкой освещенности, при оценке расстояния до предметов, приеме пищи, способности к чтению, что, по мнению авторов, связано со снижением контрастной чувствительности.…”

Section: Modern Multicenter Studies Of Psychological Features Proper unclassified

The psychology of a glaucoma patient

Габдрахманов¹,

Газизова

Селезнев³

et al. 2020

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

Современные многоцентровые исследования психологических особенностей пациентов с глаукомой свидетельствуют о наличии физиологических и психологических проблем, связанных с этим заболеванием. Высокий уровень тревоги обуславливает клинически значимое повышение внутриглазного давления. Частота депрессии и тревоги у пожилых людей с нарушениями зрения в два раза выше, чем у пожилых людей в целом. Дефицит поля зрения оказывает более неблагоприятное влияние на качество жизни пациентов с глаукомой, чем даже ухудшение остроты зрения, особенно при локализации дефекта поля зрения в нижней полусфере. Несоблюдение назначенного гипотензивного режима может быть вызвано неверием пациентов в благополучный исход заболевания, низким уровнем доверия к врачу, низким уровнем образования и низким ежемесячным доходом пациента, наличием побочных эффектов местной гипотензивной терапии, типом применяемых препаратов и их количеством. Ключевые слова: первичная открытоугольная глаукома; депрессия; тревога; качество жизни Конфликт интересов: отсутствует. Прозрачность финансовой деятельности: никто из авторов не имеет финансовой заинтересованности в представленных материалах или методах.

show abstract

“…A progressive loss of the visual field and eventually blindness characterize glaucoma, an optic neuropathy caused by the destruction of ganglion cells [ 1 ]. Glaucoma is the second most common cause of blindness worldwide, with a growing number of people affected [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Glaucoma Treatment and Hydrogel: Current Insights and State of the Art

Fea

Novarese

Caselgrandi

et al. 2022

Gels

View full text Add to dashboard Cite

Aqueous gels formulated using hydrophilic polymers (hydrogels) and those based on stimuli-responsive polymers (in situ gelling or gel-forming systems) attract increasing interest in the treatment of several eye diseases. Their chemical structure enables them to incorporate various ophthalmic medications, achieving their optimal therapeutic doses and providing more clinically relevant time courses (weeks or months as opposed to hours and days), which will inevitably reduce dose frequency, thereby improving patient compliance and clinical outcomes. Due to its chronic course, the treatment of glaucoma may benefit from applying gel technologies as drug-delivering systems and as antifibrotic treatment during and after surgery. Therefore, our purpose is to review current applications of ophthalmic gelling systems with particular emphasis on glaucoma.

show abstract

Glaucoma and Quality of Life

Cited by 19 publications

References 52 publications

Micro-Invasive Glaucoma Surgery with the iStent inject: Impact on IOP and Medication Burden in a Real-World Setting

Micro-Invasive Glaucoma Surgery with the iStent inject: Impact on IOP and Medication Burden in a Real-World Setting

The psychology of a glaucoma patient

Glaucoma Treatment and Hydrogel: Current Insights and State of the Art

Contact Info

Product

Resources

About